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Abstract
This review summarizes the major developments in animal models
of arthritis in the past decade. It focuses on novel transgenic
models, addresses the involvement of cytokines and discusses
novel findings in cartilage and bone erosion. It is clear that interest
has been raised in the direct arthritogenic role of autoantibodies,
apart from T cell involvement, and their interaction with cells
through Fcgamma receptors. In addition, a role for IL-6 and IL-17
and Th17 cells seems apparent in most T cell-driven arthritis
models, with environmental triggering through Toll-like receptors
contributing to this process. Further insights into enzymes involved
in cartilage proteoglycan loss in arthritis, as well as mediators
regulating bone erosion and bone apposition, have been gained.
Introduction
Animal models have contributed to the understanding of
basic mechanisms of joint disease. There is marked diversity
among the numerous models, and arthritis has been induced
by various stimuli. These include the generation of auto-
immunity to cartilage components, nonspecific skewing of
autoimmunity with adjuvants, and triggering with exogenous
agents such as bacteria and viruses. More recently, focused
transgenic manipulation has added novel variants (Table 1).
The wide variety of agents that can induce experimental
arthritis with histopathological features close to those of
human arthritides suggests that disparate etiological path-
ways may exist in rheumatoid arthritis (RA). No single animal
model of arthritis truly represents the human disease, but the
models mimic various aspects and can be used as tools to
understand particular pathways.
Developments over the past decade include the generation of
novel models as well as pathway analysis and therapeutic
targeting in classic models. Aspects peculiar to individual
models are of value but must be interpreted with caution.
Much can be learned from the general validity of mediator
involvement and other common concepts. This review will not
discuss the developments in immune regulation and the use
of models to identify disease susceptibility genes, but will
focus on insights into cytokine involvement and aspects of
joint destruction. The process of cartilage erosion remains
hard to evaluate in patients. Synovial biopsies are now
performed in many early arthritis clinics, but samples of
damaged bone and cartilage become available only late in the
disease, after joint replacement. Models therefore provide
valuable tools.
Characteristic histopathological features of RA include
immune complexes (ICs) in the articular cartilage layers and
variable amounts of macrophages, T cells and plasma cells in
the synovium, often accompanied by fibrosis and synovial
hyperplasia. Formation of autoantibodies, including rheuma-
toid factor and the more recently discovered anti-citrulline or
anti-citrullinated protein antibodies (ACPAs), is prominent,
making B cell activation and IC-mediated cellular inflam-
mation likely contributors to pathogenesis. Indeed,
perceptions have changed over the years and it is now
generally accepted that IC arthritis models have their value
and are increasingly used, although it must be emphasized
that erosive arthritis is only achieved with high amounts of
defined antibody cocktails. In fact, chronicity and joint
erosions of IC arthritis are markedly amplified by the presence
of a T cell component.
Models of arthritis
From a historical perspective, the models most widely used in
the past decades have been adjuvant arthritis, collagen-
induced arthritis (CIA), antigen-induced arthritis (AIA) and
streptococcal cell wall arthritis (Table 1). These models are
classic examples of three driving elements: nonspecific
immune deviation, targeted cartilage autoimmunity and
abundant exogenous/infectious triggers. T cells play a
Review
Lessons from animal models of arthritis over the past decade
Wim B van den Berg
Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, 6525 GA Nijmegen, The Netherlands
Corresponding author: Wim B van den Berg, w.vandenberg@reuma.umcn.nl
Published: 14 October 2009 Arthritis Research & Therapy 2009, 11:250 (doi:10.1186/ar2803)
This article is online at http://arthritis-research.com/content/11/5/250
© 2009 BioMed Central Ltd
ACPA = anti-citrullinated protein antibody; AIA = antigen-induced arthritis; CIA = collagen-induced arthritis; FcgR = Fcgamma receptor; GPI =
glucose-6-phosphate isomerase; IC = immune complex; IFN = interferon; IL = interleukin; RA = rheumatoid arthritis; RANKL = receptor activator of
NF-kappaB ligand; TGF = transforming growth factor; TLR = Toll-like receptor; TNF = tumor necrosis factor.Arthritis Research & Therapy    Vol 11 No 5 van den Berg
Page 2 of 10
(page number not for citation purposes)
dominant part in all of these models and this feature is a
major principle of chronic erosive arthritis. Common models
are summarized in Table 1 (see also [1-15] for further reading),
but only novel developments are now discussed in more
detail. Although T cell-directed therapy in RA was question-
able for a while, insight into T cell subclasses has grown and
more subtle targeting of CTLA4 on T cell subsets looks
promising. The recent discovery of Th17 as a distinct,
pathogenic T cell subset further boosted the interest in T cell-
driven arthritis models.
KRN arthritis
An intriguing, novel arthritis model emerged from experiments
in transgenic mice overexpressing a self-reactive T cell
receptor. K/BxN mice, which express both the T cell receptor
transgene KRN and the MHC class II molecule Ag7, develop
arthritis [16]. In principle, many insults or adjuvants that skew
regulation of T cell tolerance have the potential to create
autoimmune pathology, including joint inflammation. The
major breakthrough and beauty of the KRN model is the
elucidation of the driving antigen and the identification that
Table 1
Models of arthritis
Model Abbreviation Speciesa Feature IC T cell References
Trigger-induced models
Non-specific immune stimuli
Adjuvant-induced arthritis AA Lewis rat Autoimmune - + [1,2]
Oil-induced arthritis OIA DA rat Autoimmune - + [3]
Pristane-induced arthritis PIA DA rat Autoimmune - + [4,5]
Cartilage directed autoimmunity
Collagen-induced arthritis CIA DBA mouse CII AI + + [6,7]
Proteoglycan-induced arthritis PGIA Balb/c mouse PG AI + + [8,9]
Infectious agents/exogenous triggers
Streptococcal cell wall arthritis SCW-A Lewis rat Persistent bacteria AI - + [10]
Flare SCW-F Mouse Th17 - + [11]
Antigen-induced arthritis AIA Rabbit, mouse Persistent antigen + + [12,13]
Flare AIA-F Mouse Th17 - + [14]
Transgenic spontaneous models
HTLV-induced arthritis HTLV Mouse Viral tax antigen - + [15]
KRN arthritis KRN K/BxN mouse GPI AI + + [16,17]
SKG arthritis SKG Mouse ZAP-70 T cell defect - + [18,19]
GP130 arthritis  GP130 Mouse STAT3, T cell defect - + [20,21]
TNF transgenic arthritis TNFtg Mouse TNF overexpression - - [47,48]
IL-1ra transgenic arthritis IL-1ra-/- Balb/c mouse Autoimmune T cells ± + [23]
IL-1 transgenic arthritis IL-1tg Mouse IL-1 overexpression - - [22]
Immune complex models
Collagen type II CAIA DBA mouse Mouse CII antibody + - [26,27]
KRN serum GPI Balb/c mouse Mouse GPI antibody + - [31]
Poly-L-lysine-lysozyme PLL-L DBA mouse Cationic antigen + - [28]
aMost commonly used. AI = autoimmune; CAIA= collagen antibody-induced arthritis; GPI = glucose-6-phosphate isomerase; IC = immune
complexes as an early feature; PG = proteoglycan.passive transfer with antibodies induces protracted arthritis.
In this model, the T cell receptor recognizes the ubiquitous
self-antigen glucose-6-phosphate isomerase (GPI) and pro-
vokes, through B cell differentiation and proliferation, high
levels of anti-GPI antibodies. These antibodies are directly
pathogenic upon transfer and appear to recognize endoge-
nous cationic GPI, which seems to associate preferentially
with the cartilage surface [17]. The latter may underly the
dominance of joint pathology in these mice, although GPI is
also abundant at other sites in the body. This principle was
already identified in AIA in mice, where antigen is planted in
the knee joint of immunized mice. Cationicity of the antigen
and sticking to cartilage greatly enhances arthritogenicity
[13], demonstrating that either cartilage itself (for example,
autoimmunity to collagen type II or proteoglycans) or antigens
tightly associated with cartilage are major drivers of this. In
KRN arthritis, IgG1 antibodies are the major subclass and
cause a sustained, erosive arthritis after continued transfer,
with high sensitivity in Balb/c mice. The pathology of this
model is similar to that of passive CIA (CAIA) or IC arthritis,
with planted cartilage-associated antigen, all including IC
formation at the cartilage surface. Differences between the
models relate to the IgG subclasses involved.
SKG and gp130 arthritis
Another recent example of a transgenic T cell model is
provided by the occurrence of chronic autoimmune arthritis in
mice with a point mutation in the gene encoding ZAP-70, a
key signal transduction molecule in T cells [18]. The aberrant
T cell receptor function leads to positive selection of otherwise
negatively selected autoimmmune T cells. Of high interest,
these mice fail to develop disease under germ-free conditions
despite active production of arthritogenic autoimmune cells.
Apparently, the cells are in a resting state and need further
activation before trafficking to joints and precipitation of
arthritis occurs. A single injection of Zymosan provokes
arthritis in a Dectin-1-dependent but Toll-like receptor (TLR)-
independent manner [19]. The latter is in sharp contrast with
the arthritis in IL-1ra-/- mice, which is similarly dependent on
flora, but clearly TLR4 dependent. Th17 cells play a crucial
role in SKG arthritis and identify that environmental factors
such as yeast may drive or accelerate Th17 arthritis pathology.
Mice with a homozygous mutation in the gp130 IL-6 receptor
subunit show enhanced signal transduction and STAT3
activation and develop lymphocyte-mediated RA-like joint
disease, identifying another example of skewed T cell function
resulting in arthritis. Increased proliferation of CD4+ T cells
appeared due to elevated production of T cell-activating IL-7
by nonhematopoietic cells [20,21].
IL-1 transgenic mice and IL-1ra deficient mice
Following the development of human TNF transgenic arthritis
in the early 1990s, transgenic IL-1a overexpression was
shown to induce chronic, destructive arthritis [22]. Trans-
genic mice expressing human IL-1a had high serum levels of
IL-1 and developed severe polyarthritis by 4 weeks of age.
Hyperplasia of the synovial lining, pannus formation and,
ultimately, cartilage destruction were evident. T and B cells
were scant, but active granulocytes were abundant.
The opposite approach, elimination of IL-1 control by gene
targeting of the endogenous IL-1 receptor antagonist (IL-1ra),
yielded a T cell model of arthritis. IL-1ra deficiency in a
Balb/ca background resulted in pronounced arthritis at the
age of 8 weeks [23]. Marked synovial and periarticular inflam-
mation was noted, with invasion of granulation tissue and
articular erosion. Moreover, elevated levels of antibodies
against immunoglobulins, type II collagen and double-stranded
DNA were found, suggestive of autoimmune responses.
Intriguingly, IL-1ra deficiency in a C57Bl/6j background did
not yield arthritis, but instead showed arteritis. This genetic
variation, although not well understood, underscores an
immunologic pathogenic pathway. Overexpression of a range
of cytokines, including IL-1b, TNF and IL-6, was observed in
the joints before onset of arthritis. Interestingly, autoantibody
levels did not correlate with disease severity, which may imply
that it reflects a reaction to damaged joint tissue.
In sharp contrast to the TNF transgenic model, the arthritis in
IL-1ra-/- mice is dependent on T cells, in line with the strong
genetic restriction. It is consistent with the view that IL-1 is a
crucial regulator of T cell function. Impaired T cell activation is
demonstrated in IL-1 deficient mice, linked to low levels of
CD40 ligand and OX40 expression on T cells, and underlies
the suppression of collagen arthritis in IL-1-/- mice.
Undisturbed IL-1 action, in the absence of IL-1ra, permits
activation of IL-17-producing T cells directed against exoge-
nous triggers or endogenous autoantigens. The spontaneous
arthritis in IL-1ra-/- mice does not develop under germ-free
conditions and is reduced in TLR4-deficient mice. Both TNF
and IL-17 deficiency prevent onset of arthritis [24,25].
Immune complex arthritis
Autoantibodies like rheumatoid factor and ACPAs are a key
feature of RA and the recent success of treatment with an
anti-B cell drug (Rituximab) supports the belief that they have
a pathogenic role in it. In some of the models, such as
collagen-, proteoglycan- and antigen-induced arthritis, immune
complex formation at joint tissues is a major element of the
disease. Excessive immune complex formation can cause
destructive arthritis but chronicity is limited, although it is
greatly enhanced by T cells. The latter may be linked to the
need for T cells to sustain antibody production, and the
greater potential of T cell macrophage interaction to sustain
joint pathology. Minute amounts of antigen suffice to stimulate
T cells, whereas considerable amounts of ICs are needed to
stimulate inflammatory mediator release from phagocytes. It is
likely that IC models mimic part of the RA pathology.
There is growing interest in the use of passive IC models,
together with a range of transgenic knockouts, to identify
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advantage of passive systems is lower dependence on
genetic background, avoiding excessive back-crossing to
create transgenics in suitable, susceptible mouse strains.
Passive collagen-induced arthritis
Passive transfer of collagen arthritis can be performed with a
critical mixture of a number of anti-collagen type II
monocloclonal antibodies, including complement binding
IgG2a [26,27]. Sets are now commercially available, routinely
recommending DBA mice as sensitive recipients and
additional lipopolysaccharide injection for synchronization of
expression. Accepted concepts of inflammation pathways
include IC-mediated complement activation and Fcgamma
receptor (FcgR) triggering on phagocytes. Proteoglycan anti-
bodies from the proteoglycan arthritis model can induce
transient arthritis upon transfer, with concomitant proteo-
glycan loss from the cartilage, but no erosive damage. IgG1
seems to be the critical IgG subclass, but its destructive
potential is not yet clear.
Passive poly-L-lysine-lysozyme arthritis
An IC model emerging from the murine AIA model and using
the principle of cationic retention involves passive transfer of
anti-lysozyme antibodies to mice that are locally injected in
one knee joint with poly-L-lysine-coupled lysozyme. Poly-L-
lysine-coupled lysozyme is highly cationic and sufficiently
large to be retained in the joint for prolonged periods of time.
Both association with synovial tissue and heavy sticking to
cartilage surfaces contributes to chronicity and cartilage
destruction. An intriguing observation is the more chronic and
destructive nature of this arthritis in DBA/1j compared to
Balb/c mice [28], which seems related to high sustained
levels of activating FcgRs on macrophages of DBA/1j mice.
The model shows strong dependence on IL-1, whereas TNF
blockade was ineffective [29]. FcgRI rather than FcgRIII
appears to be crucial for cartilage damage [30].
Passive KRN/glucose-6-phosphate isomerase arthritis
Antibodies present in the serum of arthritic KRN mice are
directly pathogenic upon systemic transfer. They recognize
endogenous GPI, which seems to associate preferentially
with the cartilage surface [17,31,32]. The latter may underlie
the dominance of joint pathology in these mice, although GPI
is also abundant at other sites in the body and other
pathologies are noted as well. This observation opened a
wide search for the relevance of such antibodies in RA, but
they are not present at high levels and are not found in all
patients and their role in RA remains to be proven. IgG1
antibodies are the major IgG subclass in this model and
cause a sustained, erosive arthritis after continued transfer,
with high sensitivity in Balb/c mice [1]. Large variation is
noted in the various mouse strains, making it crucial to use
proper control mice with a defined genetic background when
pathway studies are done in particular knockout mice, which
are often available in mixed genetic backgrounds. Serum is
more active than purified anti-GPI antibodies, suggesting the
presence of arthritis-promoting cofactors such as TLR
ligands or cytokines. Repeat injections enhance chronicity
and joint destruction. The model comes close to passive CIA
and IC arthritis, with planted cartilage-associated antigen, all
having IC formation at the cartilage surface as a salient
feature.
Recently, an adaptation of this arthritis model was developed
by immunization with GPI in Freunds adjuvant. This model is a
mix of IC and T cell-driven arthritis [33,34]. Serum from this
model was not able to transfer arthritis, indicating that
antibodies generated with this immunization are poorly
arthritogenic. Upscaling or the use of a critical mixture of
multiple epitope-recognizing antibodies is needed, similar to
observations with anti-collagen type II antibodies.
Passive citrulline-induced arthritis
In line with the identification of ACPAs as an early marker of
the RA process, many groups have attempted to induce
citrulline arthritis. Consensus on whether such antibodies
occur in classic arthritis models has not yet been reached
due to inconsistencies in the detection of true ACPAs and
omission of proper controls for antibodies cross-reactive with
non-citrullinated components. In fact, many groups have
failed to detect true ACPAs and much of the circumstantial
evidence for them comes from unpublished observations.
Yet, an initial study supporting the arthritogenic role of anti-
citrulline immunity in collagen arthritis was provided by Holers
and colleagues [35]. Intriguingly, mice tolerized to citrulline
showed reduced collagen arthritis, suggestive of a contri-
bution of citrulline in CIA, although bystander suppression
rather than specific tolerization can not be excluded. In a
transgenic mouse bearing the human RA-associated shared
epitope (Dr4), it was subsequently demonstrated that arthritis
could be induced by immunization with citrullinated fibrinogen
[36], but the arthritis was different from RA or classic CIA.
Very recently, Holmdahl’s group generated a range of
antibodies specific for citrullinated collagen type II and
showed induction of arthritis upon transfer [37]. In addition,
the antibodies could amplify smoldering collagen arthritis.
This amplifying principle was also found in the past for
rheumatoid factor. The difficulty of showing arthritogenic
potential and the need for mixtures of antibodies to facilitate
arthritis expression may explain why antibodies can be
already detected 5 years before the onset of RA. Epitope
spreading [38] and the creation of a critical mix of antibodies,
allowing the generation of large polyclonal IC networks, might
be crucial.
IgG, Fcgamma receptors and complement
ICs interact with macrophages and granulocytes mainly
through FcgRs. In this decade FcgRIIb was identified as an
inhibitory receptor, regulating the activity of the activating
FcgRI and FcgRIII. Deletion of the IIb receptor renders H-2b
mice susceptible to collagen arthritis [39]. Likewise, it was
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susceptible to CIA, have a skewed FcgR balance compared
to non-susceptible C57Bl and Balb/c mice [28]. DBA mice
have high levels of the stimulatory type III receptor on resting
macrophages whereas cells from B10RIII mice have normal
levels but show skewing in favor of type III over type IIb
receptors upon triggering with inflammatory stimuli. This
argues that mice and individuals have different susceptibilities
to IC arthritis dependent on their FcgR make up.
A complicating factor in extrapolating data from mouse to
human is the fact that human cells have another dominant
activating type receptor, FcgRIIa. A transgenic mouse was
generated bearing human FcgRIIa. Intriguingly, this mouse
develops spontaneous multisystem autoimmune disease,
including arthritis with aging [40]. In addition, these mice
develop CIA more rapidly and show a severe phenotype. Of
interest, antagonists developed for this activating FcgRIIa
showed therapeutic efficacy in CIA in these mice [41].
A recent discovery in this field is the identification of a novel
receptor, FcgRIV. Its contribution to joint pathology remains
to be studied. For further reading, a review by Boross and
Verbeek is recommended [42].
Apart from triggering of FcgRs, complement activation plays a
major role in IC-mediated arthritis. Both the classic and
alternative pathways of complement activation can contribute
[43], the relative contributions of which are probably mainly
dependent on the subclasses of antibodies present, adher-
ence to joint surfaces as well as the genetic background of
the mice [17]. More recently, a major amplifying role of the
alternative pathway was identified in the passive CIA model
performed in a series of mice genetically deficient in
components of the complement pathways [44]. Intriguingly, a
novel selective inhibitor of the alternative complement pathway
markedly reversed inflammation and bone destruction [45].
Role of cytokines
Findings on the involvement of TNF, IL-1, IL-6 and IL-17 in
arthritis and concomitant joint destruction will be discussed
below in more detail. In general, TNF is a major mediator in
the early stages of joint inflammation in every experimental
arthritis model. Although IL-1 is not a dominant early inflam-
matory cytokine in all models, it is the pivotal cytokine in
inhibition of chondrocyte proteoglycan synthesis in the
articular cartilage in all models studied so far and blocking of
it has great beneficial impact on net cartilage destruction
[46]. In line with this, chronic destructive arthritis could not be
induced in IL-1 deficient mice using any of the classic arthritis
models and this holds as well for the more novel models such
as KRN and SKG arthritis and passive GPI/KRN arthritis. In
fact, both T cell- and IC-driven murine models appear IL-1
dependent. In contrast, TNF deficiency reduced the inci-
dence of autoimmune arthritis expression in most models, but
once joints became afflicted full progression to erosive
arthritis did occur in the full absence of TNF. It is not yet clear
why IL-1 is such a dominant target in IC- and T cell-driven
murine arthritis models, whereas a crucial role for IL-1 in auto-
immune RA in humans is still questionable or even unlikely.
The latter statement is based on the successful targeting of
IL-1 with IL-1ra in proven IL-1-dependent diseases such as
Mediterranean fever or gout. The identification of the novel
T cell cytokine IL-17, its role in arthritis models and the strong
dependence on IL-1 for the generation of Th17 cells in mice,
but certainly also in humans, provides an even greater
enigma. This may argue that, in human RA, the contribution of
IL-1 is overruled, or dominant pathways besides autoimmune
IC- and T cell-driven processes play a role and have yet to be
identified.
TNF/IL-1 involvement
In 1991, Kollias and coworkers provided insight into the
possible role of TNF in arthritis induction in an elegant series
of experiments. By introducing into mice a modified human
TNF transgene lacking a TNF 3’ untranslated region involved
in translational repression of TNF, it was shown that pro-
nounced TNF overexpression results in chronic polyarthritis
with a 100% incidence [47]. Hyperplasia of the synovium,
inflammatory infiltrates in the joint space, pannus formation,
and cartilage and bone destruction were observed. Intriguingly,
a similar form of arthritis also developed in targeted mutant
mice lacking the 3’ AU-rich elements, confirming the role of
these elements in the maintenance of a physiological TNF
response in the joint [48]. A proposed mechanism for this is
the inability of natural anti-inflammatory signals such as IL-10
to suppress TNF production under these conditions. These
exciting findings stimulated a major search for functional
mutations around TNF production in RA patients. However,
no clear indications have so far been found. Further investi-
gation of TNF receptor involvement showed a crucial role of
the p55 type I receptor in mediating TNF pathology, and a
suppressive role of the p75 type II receptor. This implies a
dualistic pro-inflammatory and immunosuppressive role for
TNF and heterogeneity of TNF receptor usage in autoimmune
suppression versus inflammatory tissue damage [49,50].
These observations may provide a rationale for future treat-
ment of RA with selective anti-TNF receptor instead of anti-
TNF antibodies.
The TNFtg model gained much interest and is now used in
many labs to identify downstream pathways of TNF-induced
joint pathology and to screen the efficacy of various TNF-
directed therapies. It is not surprising that anti-TNF treatment
blocks the pathology, but it is a remarkable observation that
IL-1 is a major downstream mediator. Crosses between
TNFtg and IL-1 deficient mice yielded insight into IL-1-
dependent elements and it was convincingly demonstrated
that TNF drives inflammation. However, bone erosion is partly
dependent on IL-1 and cartilage erosion is completely
dependent on it [51]. It identifies that even in a fully TNF-
driven system, IL-1 is solely responsible for cartilage erosion
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erosion scores are often dominated by bone erosion,
whereas joint space narrowing, if included, is an insensitive
measure of focal cartilage erosion and the impact of IL-1
blocking may be underestimated.
As already mentioned above, in many IC- or T cell-driven
arthritis models TNF is important at onset of disease, but less
involved at later stages, when IL-1 and IL-17 become major
players. This is found in CIA [52,53], KRN arthritis [32], SKG
arthritis [18] and spontaneous arthritis in IL-1ra-/- mice
[24,25,54]. In an attempt to create a model with stronger
macrophage involvement, yet using natural stimuli, we
repeatedly injected streptococcal cell wall fragments into the
murine knee joint, creating chronicity by repeated flares.
Earlier we showed that such flares can be achieved with both
homologous or heterologous fragments [55]. Every flare
remained TNF dependent in terms of swelling, yet chronic
infiltrate and concomitant joint erosion became IL-1 depen-
dent, and the model also displayed a gradually increasing role
of T cell-derived IL-17 and IL-17 receptor-bearing synovio-
cytes [11,56]. Recently, IL-32 was discovered as a novel
human cytokine driving TNF expression. It induces arthritis in
mice [57], but an endogenous murine analog of this cytokine
has not been found yet, hampering mechanistic studies on its
role as an upstream mediator.
IL-6/IL-17 involvement
IL-6 has been detected as an abundant cytokine in washouts
of inflamed joints under many experimental model conditions.
Although its function is pleiotropic, therapy was developed
directed at the IL-6 receptor and humanized anti-IL-6 receptor
antibodies now appear efficacious in human RA. It is already
an old observation that AIA and Zymosan-induced arthritis are
suppressed in IL-6 deficient mice [58]. Nowadays it is
becoming more clear that the underlying mechanism of this
suppression may be linked to the role of IL-6 in the generation
of pathogenic Th17 cells. Th17 cells were recently identified
as a separate T cell lineage, apart from Th1 and Th2 cells,
and numerous groups have demonstrated a crucial role for
IL-6 and IL-1, potentially together with transforming growth
factor (TGF)β, in their generation [59,60]. IL-23 appears to
be a propagation factor of Th17 cells, rather than a crucial
inducing factor. Recent studies show that blockade of IL-6
activity with anti-IL-6 receptor antibodies suppresses both
GPI [34] and CIA [61], whereas evidence was obtained of
reduced Th17 induction. Of interest, this effect was not noted
with anti-TNF treatment, making IL-6 receptor-directed
targeting a potential alternative therapy in patients refractory
to TNF blockade.
Before the identification of Th17 cells in 2005 as a separate
lineage, IL-17 was already seen as a novel cytokine displaying
arthritogenic potential apart from IL-1 and TNF. Local over-
expression using adenoviral IL-17 gene constructs showed
that it can accelerate inflammation and tissue destruction in
CIA [62], and greatly amplifies passive KRN arthritis [63],
concomitantly causing accelerated CIA and KRN arthritis
independent of IL-1 and TNF, respectively. This illustrates that
arthritis can become refractory to TNF and IL-1 blocking
when IL-17/Th17 dominates the process. Exploration of the
efficacy of anti-IL-17 antibodies in arthritis models revealed
suppression of inflammation and tissue damage in CIA [64]
and superior suppression in T cell-driven flares of AIA com-
pared to the acute stages of AIA [14]. It also revealed
suppression of spontaneous arthritis in IL-1ra-/- mice [55], in
line with the absence of this arthritis in IL-17 deficient mice
[24]. As an exception to the rule, autoimmune proteoglycan-
induced arthritis appears mainly a Th1-mediated model, in
contrast to most Th17-driven arthritis models. The reason for
this peculiar phenotype is largely unexplained. It is sup-
pressed but not completely prevented in IFNγ-deficient mice,
whereas proteoglycan-induced arthritis could be easily
elicited in IL-17-deficient mice, to demonstrate that severe
and destructive arthritis can occur independently of IL-17
[65]. Interestingly, IFNγ-deficient mice did not show complete
absence of disease, but merely a delayed onset, suggesting
an early role for Th1 cells in this model. A role for IL-17 in late
disease was unmasked in IFN/IL-17 double knockouts,
showing complete suppression of both early and late arthritis
(A Finnegan, personal communication).
Impact of environment and co-stimuli
Recently, TLRs were discovered as major receptors involved
in pattern recognition of bacteria and viruses. Using another
model of autoimmune inflammation, Luger et al. [66] showed
that conditions of disease induction affect whether the Th17
or Th1 effector category is dominant. After immunization with
retinal antigen IRBP in complete Freund’s adjuvant, IL-17-
dependent uveitis develops, whereas induction of
experimental autoimmune uveitis with IRBP-pulsed mature
dendritic cells results in the generation of an IFNγ-producing
effector response. The data indicate that the conditions of the
initial antigen exposure, including the quality/quantity of TLR
stimulation and/or type of antigen presenting cells, determine
the dominant effector phenotype. Likewise, IL-1ra-/- mice
develop spontaneous Th17-dependent arthritis under normal
housing conditions, but arthritis is completely lost under germ-
free conditions. This suggests that bacterial flora drive the
generation of autoimmune Th17 cells under conditions of
excess IL-1. Crossing studies with various TLR deficient mice
identified that TLR4, in particular, was responsible for skewing
towards Th17 responses and development of an erosive
arthritis phenotype [67]. Of therapeutic interest, TLR4
blocking, using a receptor antagonist, blocked both IL-1ra-/-
arthritis as well as CIA [68], identifying TLR4 as a novel target.
As an aside, passive KRN arthritis is IL-1 dependent and is
greatly reduced in IL-1R deficient mice. Intriguingly, when the
TLR4 agonist lipopolysaccharide is applied as an additional
stimulus, IL-1 dependency is overruled and arthritis pro-
gresses undisturbed [69]. It illustrates that lipopolysaccharide
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be lost in the presence of such environmental co-stimuli.
We need to be aware that animal models are strongly
restricted in terms of exposure to environmental triggers
common to humans due to clean pathogen controlled housing
conditions. As an example, a link between smoking and
occurrence of ACPAs has been demonstrated in RA patients,
a condition not encountered in experimental studies with mice.
Crucial synovial cells
The local architecture of the synovial tissue is of prime
importance for arthritis expression. We showed earlier that
depletion of synovial lining cells using chlodronate laden
liposomes prevents expression of arthritis [70], in line with a
major role for these cells in local cytokine and chemokine
production. A major development was the identification of
Cadherin 11 as a crucial factor in the organization of synovial
architecture. Cadherin 11 deficient mice have a hypoplastic
synovial lining, display a disorganized synovial reaction to
inflammation and are resistant to inflammatory arthritis [71].
Cadherin-11 therapeutics prevent and reduce arthritis in
mice. Apart from synovial lining cells, the presence of mast
cells makes a joint vulnerable to arthritis expression. Mast cell
deficient mice lose susceptibility to passive GPI arthritis,
identifying mast cell activation and concomitant IL-1 release
as a dominant feature in the precipitation of arthritis at distinct
sites [72]. This is in keeping with the old observation that
preferential expression of arthritis occurs at sites that contain
abundant numbers of mast cells, such as footpads.
Cartilage and bone destruction
Animal models are excellent tools to characterize destructive
pathways. Cartilage damage observed in models ranges from
a reversible loss of proteoglycans to collagen damage, cell
death and complete surface erosion. This underlines that
arthritic processes can be more or less destructive,
dependent on the underlying (immune) process and cytokine
mixture [73]. Collagen breakdown and aggressive cartilage
loss is predominantly noted in the presence of immune
complex deposition, whereas milder, more gradual forms of
damage are seen in models driven by macrophage or T cell
activation. Large variation in progressive destruction is also
observed in patients with RA, with the presence or absence of
autoantibodies (rheumatoid factor, ACPAs) contributing to this.
It was long debated whether proteoglycan loss contributes to
erosive damage. Elegant studies were performed in ADAMTS4
and ADAMTS5 knockout mice, which are deficient in the
major enzymes involved in the degradation of aggrecan, the
dominant proteolgycan of articular cartilage. One identified
the crucial role of ADAMTS5 in early proteoglycan loss in AIA
[74]. In addition, aggrecan knockin mice were generated with
a mutation in the major aggrecanase cleavage site, making
the aggrecan resistant to specific breakdown. Intriguingly,
cartilage erosion was not only diminished in AIA in these
mice, but cartilage repair was stimulated following inflam-
mation [75]. This makes ADAMTS5 a promising target in RA,
potentially preventing erosive collagen damage if treatment is
started early enough. The cytokines TNF, IL-1 and IL-17 can
drive aggrecanase production, but other mediator systems
can as well, making enzyme targeting warranted. As an aside,
experimental osteoarthritis is also markedly reduced in
ADAMTS5 knockouts [76], identifying a promising thera-
peutic target in this disease with large unmet medical needs.
Apart from aggrecanases, studies in immune models in
various FcgR knockout mice further identified that FcgRI is
pivotal in driving IC-mediated cell activation, metallo-
proteinase activation and concomitant cartilage erosion
[77-79]. This receptor or its downstream activation pathways
provide challenging therapeutic targets. Of great interest, the
absence of FcgRI blocked cartilage damage, yet had no
impact on bone erosion. In fact, bone erosion is independent
of FcgRs. Arthritis in FcgRI, II and III knockouts is pronounced
and sustained due to defective clearance of ICs and cartilage
erosion is absent although bone erosion is enhanced, in line
with enhanced cytokine production under these conditions.
Cytokines like TNF, IL-1 and IL-17 cause bone erosion
through up-regulation of receptor activator of NF-kappaB
ligand (RANKL), formerly called osteoprotegerin ligand [80].
Like cartilage damage, bone erosion may occur uncoupled of
inflammation. Local gene transfer with IL-4 did not suppress
joint inflammation, yet markedly reduced cartilage and bone
destruction in CIA through suppression of RANKL [81]. Like-
wise, in RANKL deficient mice, joint inflammation continues in
passive KRN/GPI IC arthritis, but bone erosion is prevented
[82]. Similarly, when TNF transgenic mice were crossed with
c-fos deficient mice, joint inflammation continued, yet bone
erosion was fully absent. c-fos mice lack functional
osteoclasts and in this background TNFtg mice show a non-
destructive phenotype. In line with this, treatment with
osteoprotegerin, which is the natural inhibitor of RANKL, did
not reduce inflammation in adjuvant arthritis and TNF
transgenic mice, yet bone erosion was reduced [83].
The above examples identify that inflammation, bone erosion
and cartilage erosion are separate processes, potentially
needing selective therapy. Further improvement of therapy,
including for bone repair, can be achieved with the combined
blocking of cytokines and RANKL, together with an additional
bone anabolic stimulus such as parathyroid hormone [84,85].
Models also demonstrate that bone repair is evident when
inflammation wanes, but cartilage repair is more difficult to
achieve and is often defective. Anabolic stimulation and
tissue engineering approaches are needed when structural
damage is too far advanced
A final remark regards bone erosion versus bone apposition.
Unlike the situation in RA patients, many arthritis models
show bone erosion but also pronounced new bone formation
Available online http://arthritis-research.com/content/11/5/250
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prominent example, characterized by major bone apposition
early in the process, with limited to no cartilage erosion in the
beginning and inflammation as well as bone erosion
predominantly located in the bone marrow areas; however,
KRN arthritis and CIA also show pronounced bone
apposition. This apposition is less in arthritis in IL-1ra-/- mice
and virtually absent in TNFtg mice, both models showing a
gradual but slow progression of arthritis. Of great interest, a
TNF-inducible regulator of bone apposition, Dickkopf-1 (DKK-
1), was recently identified [86]. By inhibiting DKK-1, a
regulatory molecule of the Wnt pathway, the bone destructive
pattern was inhibited in TNFtg mice and reversed to a bone
forming pattern, resembling osteoarthritis. This might indicate
that most murine arthritis models are relatively devoid of TNF
compared to human RA. Of interest, we have identified TGFβ
as a major driver of osteophytes in experimental osteoarthritis
[87]. TGFβ levels are high in both experimental osteoarthritis
and RA models, suggesting that the balance between it and
other regulators such as DKK-1 is important.
Conclusion
Models are tools that mimic aspects of human disease. It is
clear that animal models have contributed considerably to
further our understanding of arthritic processes and conco-
mitant cartilage and bone destruction, and have provided
novel insights and treatment targets. However, final proof of
the use of data determined using these models lies in clinics;
time will tell whether model data are predictable for certain
targets and, as such, clinical data will help shape and define
the models. TNF and IL-6 are good examples of molecules
with general pro-inflammatory roles that were identified in
various models and against which targeted therapies with
antibodies have shown consistent efficacy in human RA.
RANKL also seems to fit into this category, with a consistent
role in bone erosion in many conditions. IL-17 seems a
promising target, and we await further identification of its role
in subgroups of RA with a distinct T cell signature. Increasing
support for a pathogenic role of autoantibodies in RA has
shifted the interest of researchers to passive IC models such
as KRN serum transfer or passive CIA (collagen II antibody
transfer). Their use is biased by ease of induction. In addition,
it remains a concern that these models are strongly IL-1
dependent whereas the role of IL-1 in RA patients seems
limited to destructive processes. 
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